Approval · Notice of Compliance 8316 · 2006
ENABLEX: Notice of Compliance 8316
Issued October 16, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8316
- Date
- October 16, 2006
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in site of manufacture
- Therapeutic class
- Muscarinic m3 selective receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENABLEX | Not yet assigned | — |
Medicinal ingredients
- DARIFENACIN HYDROBROMIDE 7.5 MG per TAB